Physician profile
Jon M Twining
NPI 1568492346
$14,068.02
in general payments reported to CMS, 2019-2025
40 companies · $2,353 in 2025
The $2,353 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,786 · 2020: $1,028 · 2021: $811 · 2022: $3,337 · 2023: $1,583 · 2024: $2,170 · 2025: $2,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,029 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,028.69 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,332.49 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $3,259.09 | 2019-2025 | Rinvoq, Skyrizi, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,690.11 | 2019-2025 | |
| Amgen INC. | $954.87 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $750.02 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $686.49 | 2019-2025 | Taltz, Zepbound |
| Regeneron Healthcare Solutions, INC. | $297.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $285.06 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $252.64 | 2020-2021 | |
| Pfizer INC. | $241.22 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $240.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $236.57 | 2022-2025 | Saphnelo |
| Ucb, INC. | $200.57 | 2019-2025 | Bimzelx, Cimzia |
| Genentech USA, INC. | $168.91 | 2019-2025 | Actemra |
| Medexus Pharma, INC. | $164.82 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Twining listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.